Tirzepatide is a once-weekly, dual-incretin peptide it activates both the GIP and the GLP-1 receptor from a single molecule and in published obesity trials it has produced some of the largest average weight reductions of any incretin agent studied to date
Immune Support : Boosting the bodys natural defenses
Regional expansion continues to shape the competitive landscape of the GLP-1 Drug Market
Given that both GIP receptor agonism and antagonism have only been thoroughly investigated in combination with GLP-1 receptor agonism, long-term clinical studies of GIP receptor antagonism alone are needed to evaluate the adverse effect profile
Scott Keatley, a registered dietitian and co-owner of Keatley MNT, explains: "This lower energy intake can result in less fuel for the body to convert into energy, thereby potentially causing feelings of tiredness or fatigue." In simpler terms, when your body doesnt get enough calories, it doesnt have the fuel it needs to keep you energized, which can leave you feeling exhausted
